矮小症的影响因素及治疗进展
Influencing Factors and Treatment Progress of Short Stature
DOI: 10.12677/ACM.2022.122147, PDF,   
作者: 孙 越, 李元霞：延安大学附属医院儿科一病区，陕西 延安
关键词: 矮小症；治疗；重组人生长激素；Short Stature； Treatment； Recombinant Human Growth Hormone
摘要: 矮小症是指在相似环境下，儿童的身高处于同种族、同年龄、同性别正常健康儿童生长曲线第3百分位数以下、或低于2个标准差者，并且每年生长速度低于5 cm。据2000年世界卫生组织报道，发展中国家矮小症的患病率高达32.5%，我国矮小症患儿人数也较庞大，成为目前儿科内分泌门诊最常见的疾病之一。对患儿生活、学习、社交、心理健康乃至以后的就业、婚姻造成很大影响。故而本文主要对它的影响因素及治疗进展进行了综述，为降低其发病率和不良预后提供参考。
Abstract: Short stature is defined as a child whose height is below the third percentile or more than 2 standard deviations of the normal healthy child growth curve for the same race, age, and sex, and whose growth rate is less than 5 centimeters per year in similar circumstances. According to the report of the World Health Organization in 2000, the prevalence of short stature in developing countries is as high as 32.5%, and the number of children with short stature in China is also large. Short stature has become one of the most common diseases in pediatric endocrinology clinic because of its great influence on children’s life, study, mental health and even future employment and marriage. Therefore, this paper mainly reviews the influencing factors and treatment progress of the disease to provide reference for reducing the incidence and poor prognosis of the disease.
文章引用：孙越, 李元霞. 矮小症的影响因素及治疗进展[J]. 临床医学进展, 2022, 12(2): 1007-1013. https://doi.org/10.12677/ACM.2022.122147

参考文献

[1] 荣月芳, 姜琴, 徐晓莉, 等. “快乐成长之家”对矮小症儿童激素替代治疗依从性的影响[J]. 交通医学, 2019, 33(2): 198-200.
[2] 李晓静, 罗飞宏, 裴舟, 等. 1496例矮小症病因分析及基于IGF-1水平生长激素缺乏症诊断预测模型的建立[J]. 临床儿科杂志, 2012, 30(12): 1110-1115.
[3] 黎海芪. 生长发育是儿科学的基石[J]. 中华儿科杂志, 2020, 58(3): 185-187.
[4] 刘朔. NPR2基因与矮小症关系的研究进展[J]. 天津医科大学学报, 2020, 26(1): 86-90.
[5] 余小霞. 矮小症患儿的病例分析及病因探讨[J]. 当代医学, 2020, 26(25): 90-92.
[6] 倪佳, 辛颖. 儿童特发性矮小的诊治进展[J]. 中国中西医结合儿科学, 2015, 7(3): 199-202.
[7] 韩晓伟, 董治亚, 张婉玉, 等. 矮小症病因及临床特征分析[J]. 临床儿科杂志, 2019, 37(1): 39-42.
[8] 王春燕, 李乐. 6-10岁儿童维生素D营养状况调查与现状分析[J]. 黑龙江中医药, 2020, 49(3): 182-183.
[9] 梁小虹, 谭迪, 简杨湄. 特发性矮小症患儿血清25(OH)D、IGF-1水平与体质量的相关性[J]. 海南医学, 2020, 31(7): 841-844.
[10] 刘捷, 李卫芹. 天津市婴幼儿维生素D水平及维生素D补充剂应用现状调查[J]. 中华实用儿科临床杂志, 2017, 32(19): 1471-1474.
[11] 刘玉, 张培, 任立群. 探究早期维生素D补充对儿童生长发育及肠道菌群的作用[J]. 中华实用儿科临床杂志, 2017, 32(19): 1471-1474.
[12] 黄洁兴. 微量元素在儿童生长发育中的作用[J]. 中国现代药物应用, 2013, 7(23): 219-220.
[13] Otsubo, Y., Hashimoto, K., Kanbe, T., et al. (2017) Association of Cord Blood Chemokines and Other Biomarkers with Neonatal Complications Following Intrauterine Inflammation. PLoS ONE, 12, e0175082. [Google Scholar] [CrossRef] [PubMed]
[14] 魏淑丽, 姚跃英, 黄雪玲. 微量元素在低出生体质量儿生长发育过程中的状况研究[J]. 川北医学院学报, 2019, 34(5): 589-591.
[15] Lakhallittleton, S. (2019) Cardiomyocyte Hepcidin: From Intracellular Iron Homeostasis to Physiological Function. Vitamins and Hormones, 110, 189-200. [Google Scholar] [CrossRef] [PubMed]
[16] 李明瑛. 微量元素对儿童生长发育的影响[J]. 中国伤残医学, 2013, 21(11): 260-261.
[17] Yin, Y., Li, Q., Sun, B., et al. (2015) Pilot Study of the Association of Anemia with the Levels of Zinc, Copper, Iron, Calcium, and Magnesium of Children Aged 6 Months to 3 Years in Beijing, China. Biological Trace Element Research, 168, 15-20. [Google Scholar] [CrossRef] [PubMed]
[18] 郑雨芝, 曹璐佳, 刘玉燕, 张静雯, 施风兰, 满意, 闫婧, 黄国伟. 天津市4618例0-3岁婴幼儿微量和常量元素检测结果分析[J]. 中国妇幼保健, 2019, 34(1): 88-90.
[19] 徐文英, 王军, 武荣. 小胎龄早产儿宫外生长发育迟缓的临床分析[J]. 中国医药导报, 2014, 11(15): 39-42.
[20] Wilson, R.L., Biancomiotto, T., Leemaqz, S., et al. (2018) Early Pregnancy Maternal Trace Mineral Status and the Association with Adverse Pregnancy Outcome in a Cohort of Australian Women. Journal of Trace Elements in Medicine and Biology, 46, 103-109. [Google Scholar] [CrossRef] [PubMed]
[21] 陈华琼. 矮身材儿童血清锌、铁、铜、钙、镁含量分析[J]. 中国儿童保健杂志, 2006, 14(3): 290-292.
[22] 李彦晓, 徐灵敏, 宋宗先, 孙文鑫. 矮小症患儿血清游离脂肪酸异常增高的临床意义[J]. 中国医刊, 2020, 55(8): 867-869.
[23] 张莹, 陈瑞敏, 杨晓红, 袁欣, 林祥. 重组人生长激素联合来曲唑治疗男性青春期矮小临床分析[J]. 中国实用儿科杂志, 2019, 34(9): 775-779.
[24] 于佳雪, 徐亚伟, 肖丹, 等. 游离脂肪酸与心血管疾病[J]. 现代生物医学进展, 2013, 13(10): 1979-1982.
[25] Xu, R., Wang, Q., Yan, M., et al. (2002) Orexin-A Augments Voltage-Gated Ca2+ Currents and Synergistically Increases Growth Hormone (GH) Secretion with GH-Releasing Hormone in Primary Cultured Ovine Somatotropes. Endocrinology, 143, 4609-4619. [Google Scholar] [CrossRef] [PubMed]
[26] Galescu, O.A., Crocker, M.K., Altschul, A.M., et al. (2018) A Pilot Study of the Effects of Niacin Administration on Free Fatty Acid and Growth Hormone Concentrations in Children with Obesity. Pediatric Obesity, 13, 30-37. [Google Scholar] [CrossRef] [PubMed]
[27] 杨旭, 刘勇毅, 阙隆盛. 儿童矮小症的治疗进展[J]. 现代医药卫生, 2011, 27(8): 1197-1198.
[28] 许乔雯, 叶进. 特发性矮小症中西医治疗进展[J]. 山东中医药大学学报, 2015, 39(6): 569-571.
[29] 苏喆, 杜敏联. 对特发性身材矮小儿童诊断和治疗的共识声明生长激素研究学会、Lawson wilkins儿科内分泌学会及欧洲儿科内分泌学会专题研讨会纪要[J]. 中华内分泌代谢杂志, 2009, 25(1): 100-102.
[30] 刘建平, 黄路圣, 叶林华. 胰岛素样生长因子-1水平监测在重组人生长激素治疗特发性矮小症中的临床意义[J]. 现代中西医结合杂志, 2017, 26(32): 3568-3571.
[31] 齐鸿涛, 赵辉. 依据类胰岛素生长因子水平调整重组人生长激素治疗特发性矮小的有效性分析[J]. 中华临床医师杂志(电子版), 2016, 10(14): 2054-2057.
[32] 吴迪, 冯国双, 巩纯秀, 等. 生长激素治疗特发性矮小儿童随访至接近成年终身高的治疗效果分析[J]. 首都医科大学学报, 2018, 39(1): 92-97.
[33] Savendahl, L., Blankenstein, O., Oliver, I., et al. (2012) Gender Influences Short-Term Growth Hormone Treatment Response in Children. Hormone Research in Paediatrics, 77, 188-194. [Google Scholar] [CrossRef] [PubMed]
[34] Ross, J.L., Lee, P.A., Gut, R., et al. (2015) Attaining Genetic Height Potential: Analysis of Height Outcomes from the ANSWER Program in Children Treated with Growth Hormone over 5 Years. Growth Hormone & IGF Research, 25, 286-293. [Google Scholar] [CrossRef] [PubMed]
[35] 常波, 苏芊. 矮身材的治疗进展[J]. 中国中西医结合儿科学, 2015, 7(3): 207-212.
[36] 朱灵芝, 茹锦岩, 俞慧君, 等. 儿童生长贴联合重组人生长激素治疗特发性矮小症的疗效[J]. 中国现代医生, 2019, 57(10): 65-67, 71.
[37] 陆新杰, 朱俊. 重组人生长激素治疗特发性矮小症的临床观察[J]. 临床合理用药杂志, 2016, 9(25): 26-27.
[38] 朱顺叶, 陈红珊, 等. 蛋白同化类固醇激素对GnRHa治疗后中枢性性早熟患儿生长的影响[J]. 中国儿童保健杂志, 2009, 17(1): 51-53.
[39] Mul, D., Oostdijk, W., Otten, B.J., et al. (2000) Final Height after Gonadotropin-Releasing Hormone Agonist Treatment for Central Precocious Puberty. Journal of Pediatric Endocrinology and Metabolism, 13, 765-772. [Google Scholar] [CrossRef] 
[40] Alessandra, V., Simona, P., Marta, V., et al. (2006) Final Height in Girls with Central Idiopathic Precocious Puberty Treated with Gonadotropin-Releasing Hormone Analog and Oxandrolone. The Journal of Clinical Endocrinology & Metabolism, 91, 1284-1287. [Google Scholar] [CrossRef] [PubMed]
[41] 宋靖荣, 董焱. AI联合rhGH对男性特发性矮小症患儿生长速率、骨密度及骨代谢的影响[J]. 医学综述, 2020, 26(24): 4952-4956.
[42] 王春林, 梁黎. 第三代非甾体类芳香化酶抑制剂在儿科内分泌临床应用中的再认识[J]. 浙江大学学报(医学版), 2019, 39(5): 298-301.
[43] Chernausek, S.D., Backeljauw, P.F., Frane, J., et al. (2007) Long-Term Treatment with Recombinant Insulin-Like Growths Factor (IGF-1) in Children with Severe IGF-1 Deficiency Due to Growth Hormone Insensitivity. The Journal of Clinical Endocrinology and Metabolism, 92, 902-910. [Google Scholar] [CrossRef] [PubMed]
[44] 刘芳, 陈俐君, 晏世玲. 重组人生长激素治疗青春期早期特发性矮小症对骨代谢的影响[J]. 儿科药学杂志, 2019, 25(6): 26-29.
[45] 马亚伟. 研究分析矮小症患儿的发病原因及诊治措施[J]. 中国保健营养, 2020, 30(27): 144-145.
[46] 徐桂林. 赖氨酸联合维生素E治疗矮小症患儿的临床疗效[J]. 全科口腔医学电子杂志, 2020, 7(5): 179.
[47] Gardner, M., Boshart, M.L., Yeguez, C.E., et al. (2016) Coming Up Short: Risks of Bias in Assessing Psychological Outcomes in Growth Hormone Therapy for Short Stature. The Journal of Clinical Endocrinology, 101, 23-30. [Google Scholar] [CrossRef] [PubMed]
[48] 陈凌华, 赵慧, 张素珍, 等. 矮小症儿童主观生活质量和社会适应能力的研究[J]. 中国儿童保健杂志, 2016, 24(12): 1271-1273.

为你推荐